H Whitford
Overview
Explore the profile of H Whitford including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
116
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Predicting Patient Status in Chronic Thromboembolic Pulmonary Hypertension Using a Biophysical Model
Ebrahimi B, Khwaounjoo P, Argus F, Chan H, Nash M, McGiffin D, et al.
Annu Int Conf IEEE Eng Med Biol Soc
. 2023 Dec;
2023:1-4.
PMID: 38083065
Chronic thromboembolic pulmonary hypertension (CTEPH) involves abnormally high blood pressure in the pulmonary vessels and is associated with small vessel vasculopathy and pre-capillary proximal occlusions. Management of CTEPH disease is...
2.
Strange G, Rose M, Kermeen F, ODonnell C, Keogh A, Kotlyar E, et al.
Intern Med J
. 2015 May;
45(9):944-50.
PMID: 26011062
Background: The management of children with congenital heart disease (CHD) has improved over recent decades and several patients surviving with CHD into adulthood are increasing. In developed countries, there are...
3.
OCarrigan B, Fournier M, Olver I, Stockler M, Whitford H, Toner G, et al.
Intern Med J
. 2014 Aug;
44(8):813-7.
PMID: 25081047
This is the first prospective study in a contemporary Australian/New Zealand population to determine the prevalence of testosterone deficiency in testicular cancer survivors at 12 months from treatment, and any...
4.
Salamonsen M, Keating D, Whitford H, Bailey M, Miller T, Manterfield C, et al.
Intern Med J
. 2010 Aug;
41(3):245-51.
PMID: 20681957
Background: IVI epoprostenol is the only therapy for pulmonary arterial hypertension (PAH) with a randomized controlled trial demonstrating improved survival, when used as first-line monotherapy. In Australia it is used...
5.
Keating D, Levvey B, Kotsimbos T, Whitford H, Westall G, Williams T, et al.
Transplant Proc
. 2009 Mar;
41(1):289-91.
PMID: 19249537
Interstitial lung disease (ILD) has been reported to have a poor outcome following lung transplantation due to difficulties getting ill recipients to transplantation and challenging early postoperative outcomes. To assess...
6.
Zheng L, Walters E, Wang N, Whitford H, Orsida B, Levvey B, et al.
J Heart Lung Transplant
. 2004 Apr;
23(4):446-55.
PMID: 15063404
Background: Inhaled fluticasone propionate (FP) therapy decreases inflammation and sub-basement membrane thickness in asthmatic airways. Bronchiolitis obliterans syndrome (BOS) in lung transplant recipients (LTRs) involves progressive airway fibrosis and obliteration....
7.
Ward C, Walters E, Zheng L, Whitford H, Williams T, Snell G
Eur Respir J
. 2002 Apr;
19(3):472-8.
PMID: 11936525
Macrophages, neutrophils and infection have been implicated in the genesis of the bronchiolitis obliterans syndrome (BOS) post lung transplantation. sCD14 is a soluble form of a shed-cell surface protein. It...
8.
Ward C, Whitford H, Snell G, Bao H, Zheng L, Reid D, et al.
J Heart Lung Transplant
. 2001 Oct;
20(10):1064-74.
PMID: 11595561
Recent publications have demonstrated potentially pathologic changes in bronchoalveolar lavage (BAL) from clinically stable lung transplant recipients (SLTRs), but there are few available data on alveolar macrophages (AMs). We formulated...
9.
Snell G, Levvey B, Chin W, Kotsimbos A, Whitford H, Williams T, et al.
Transplant Proc
. 2001 Mar;
33(1-2):1084-5.
PMID: 11267201
No abstract available.
10.
Reid D, Walters E, Johns D, Whitford H, Ward C, Khov S, et al.
J Heart Lung Transplant
. 2001 Mar;
20(2):260.
PMID: 11250524
No abstract available.